Erectile Dysfunction Drugs Market
Segments - by Products (Viagra, Levitra/Staxyn, Stendra/Spedra, Zydena, and Vitaros) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global erectile dysfunction drugs market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising patients’ awareness about the disorder and growing base of the geriatric population globally.
Erectile dysfunction, also known as impotent, refers to a health disorder that causes constant inability to succor an erection enough for sexual intercourse. Clinically, erectile dysfunction can be understood as a separate issue that is different from other issues that interfere with sexual intercourse. The shortage of crucial medical needs and the rapid rise in the number of cases of the COVID-19 cases have shifted in the progress of health facilities. The supply chain disruption and travel restrictions have created negative outlook of various major market players especially due to drug shortage worldwide. Lockdown and government restrictions have negatively impacted the import and export of drugs across the globe owing to the shortage of medicines with many people being denied access to drugs.
The dysfunction is one of the most commonly occurred health condition especially among men and its prevalence widely increases when an individual is becoming older. Older men and aging population have comorbidities such as chronic obstructive pulmonary disease, diabetes mellitus, cardiovascular diseases, and hypertension. In addition, they simultaneously prefer a medical practitioner for impairments in sexual function mostly for erectile dysfunction. The increase in the number of erectile dysfunction cases is frequently linked with the diabetes, high growth of obesity, and cardiovascular disorders.
Market Trends, Drivers, Restraints, and Opportunities
- Rising acceptance of a sedentary lifestyle and increasing prevalence of lifestyle diseases are further anticipated to boost the market growth in the coming years.
- Government and public awareness initiatives to control and diagnose of the disorder is expected to drive market growth during the forecast period.
- Economic development, healthcare infrastructure establishment, and several clinical drugs development are key factors estimated to provide potential growth rate of the market.
- Availability of cost-effective drugs and increase rate of adoption by the patients are key factors propelling the erectile dysfunction drugs market growth.
- Adverse reactions from the existing drugs and unmet clinical needs are expected to hamper the market growth.
Scope of the Report
The report on the global erectile dysfunction drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Erectile Dysfunction Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Products (Viagra, Levitra/Staxyn, Stendra/Spedra, Zydena, and Vitaros) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Bayer AG; Produtos Quimicos Farmaceuticos Ltd.; Cristalia Dong-A Pharmaceutical Co. Ltd.; Meda Pharmaceuticals, Inc.; Pfizer, Inc.; Eli Lilly and Company; S.K. Chemicals Co. Ltd.; Vivus, Inc.; and Apricus Biosciences Inc. |
Market Segment Insights
Zydena segment is expected to grow at a rapid pace
Based on products, the global erectile dysfunction drugs market is segregated into viagra, levitra/staxyn, stendra/spedra, zydena, and vitaros. The zydena segment is expected to grow at a rapid pace during the forecast period owing to its long duration of action and less incidences of adverse reactions such as vision disturbances and muscle pain. However, the viagra segment is anticipated to expand at a significant growth rate during the forecast period due to increased adoption rate among men.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the coming years owing to presence of a well-established healthcare infrastructure and increased demand for erectile dysfunction drugs in the region. The market of Asia Pacific, however, is anticipated to expand rapidly during the forecast period due to rising prevalence of erectile dysfunction causing infections, flourishing generic drugs industry, and social stigma in the region.
Segments
Segments Covered in the Report
The global erectile dysfunction drugs market has been segmented on the basis of
Products
- Viagra
- Levitra/Staxyn
- Stendra/Spedra
- Zydena
- Vitaros
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Bayer AG
- Produtos Quimicos Farmaceuticos Ltd.
- Cristalia Dong-A Pharmaceutical Co. Ltd.
- Meda Pharmaceuticals, Inc.
- Pfizer, Inc.
- Eli Lilly and Company
- S.K. Chemicals Co. Ltd.
- Vivus, Inc.
- Apricus Biosciences Inc.
Competitive Landscape
Key players competing in the global erectile dysfunction drugs market are Bayer AG; Produtos Quimicos Farmaceuticos Ltd.; Cristalia Dong-A Pharmaceutical Co. Ltd.; Meda Pharmaceuticals, Inc.; Pfizer, Inc.; Eli Lilly and Company, S.K. Chemicals Co. Ltd.; Vivus, Inc.; and Apricus Biosciences Inc. The main market players are continuously engaged in several business development activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market position.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Erectile Dysfunction Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Erectile Dysfunction Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Erectile Dysfunction Drugs Market - Supply Chain
4.5. Global Erectile Dysfunction Drugs Market Forecast
4.5.1. Erectile Dysfunction Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Erectile Dysfunction Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Erectile Dysfunction Drugs Market Absolute $ Opportunity
5. Global Erectile Dysfunction Drugs Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Erectile Dysfunction Drugs Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
6. North America Erectile Dysfunction Drugs Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
7. Latin America Erectile Dysfunction Drugs Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
8. Europe Erectile Dysfunction Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Erectile Dysfunction Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Erectile Dysfunction Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Erectile Dysfunction Drugs Market: Market Share Analysis
11.2. Erectile Dysfunction Drugs Distributors and Customers
11.3. Erectile Dysfunction Drugs Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Bayer AG
11.4.2. Produtos Quimicos Farmaceuticos Ltd.
11.4.3. Cristalia Dong-A Pharmaceutical Co. Ltd.
11.4.4. Meda Pharmaceuticals, Inc.
11.4.5. Pfizer, Inc.
11.4.6. Eli Lilly and Company
11.4.7. S.K. Chemicals Co. Ltd.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Erectile Dysfunction Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Erectile Dysfunction Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Erectile Dysfunction Drugs Market - Supply Chain
4.5. Global Erectile Dysfunction Drugs Market Forecast
4.5.1. Erectile Dysfunction Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Erectile Dysfunction Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Erectile Dysfunction Drugs Market Absolute $ Opportunity
5. Global Erectile Dysfunction Drugs Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Erectile Dysfunction Drugs Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
6. North America Erectile Dysfunction Drugs Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
7. Latin America Erectile Dysfunction Drugs Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
8. Europe Erectile Dysfunction Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Erectile Dysfunction Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Erectile Dysfunction Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Erectile Dysfunction Drugs Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Erectile Dysfunction Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Erectile Dysfunction Drugs Market: Market Share Analysis
11.2. Erectile Dysfunction Drugs Distributors and Customers
11.3. Erectile Dysfunction Drugs Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Bayer AG
11.4.2. Produtos Quimicos Farmaceuticos Ltd.
11.4.3. Cristalia Dong-A Pharmaceutical Co. Ltd.
11.4.4. Meda Pharmaceuticals, Inc.
11.4.5. Pfizer, Inc.
11.4.6. Eli Lilly and Company
11.4.7. S.K. Chemicals Co. Ltd.
Our Clients
Related Reports
Some other reports from this category!
